Employees: 1,748
Size Zeria Pharmaceutical (4559.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $552M, the 1015th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,077 on 18 Nov 2026.
Performance Over six months the shares fell 11.6%, against -20.3% for the median peer and -1.4% for the Japan market (cap-weighted) — 5th highest of 19 in its peer set.
Growth Revenue grew 11.6% over the last twelve months (peer median +0.7%); the operating margin is 15.2% (peer median 6.4%).
Valuation It trades at 9.6× forward earnings against a peer median of 11.3× (3rd cheapest of 10).
Price implies For today's price to make sense, revenue must grow about -12% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -23 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.4 points above its cost of capital (5.0% WACC).
Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥94.7B | ¥89.2B | ¥87.3B | ¥75.7B | ¥68.4B |
| Revenue growth | — | +2% | +15% | +11% | — |
| Gross profit | ¥68.6B | ¥59.4B | ¥58.1B | ¥50.2B | ¥45.1B |
| EBITDA | ¥22.8B | ¥19.7B | ¥19.8B | ¥17.3B | ¥15.2B |
| Net income | ¥10.7B | ¥8.45B | ¥9.94B | ¥7.73B | ¥6.20B |
| Free cash flow | n/a | ¥7.59B | ¥11.5B | ¥9.28B | ¥10.8B |
| Capital expenditure | n/a | ¥2.90B | ¥2.73B | ¥3.90B | ¥2.66B |
| Total debt | ¥37.0B | ¥40.4B | ¥42.4B | ¥47.6B | ¥50.7B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4559.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.4% | -11.4% | 2nd highest of 20 |
| 6-month return | -11.6% | -20.3% | 5th highest of 19 |
| Distance from 52-week high | -14.7% | -42.8% | highest of 20 |
| Revenue growth (TTM) | +11.6% | +0.7% | 8th highest of 20 |
| Operating margin | 15.2% | 6.4% | 5th highest of 19 |
| Forward P/E | 9.6× | 11.3× | 3rd cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | -12.3% | 1.0% | 2nd least demanding of 10 |
| Growth delivered (Del g) | +11.1% | +9.7% | 5th highest of 10 |
| Hurdle (Req g minus delivered) | -23.4 pp | -8.7 pp | 2nd least demanding of 10 |
| ROIC minus cost of capital | +3.4 pp | -3.5 pp | 3rd highest of 17 |
| EV / EBITDA | 4.2× | 18.5× | cheapest of 8 |
| Net debt / EBITDA | 0.3× | 0.8× | 5th least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zeria Pharmaceutical 4559.T | Japan | $552M | -12% | +12% | 15% | 9.6× | -12.3% | +11.1% |
| Zevra Therapeutics ZVRA | United States | $552M | -9% | +75% | 31% | 11.3× | -4.9% | +51.6% |
| Jinhe Biotechnology 002688.SZ | China | $550M | -19% | +7% | 5% | 8.9× | 1.0% | +9.7% |
| Boryung 003850.KS | South Korea | $554M | -13% | +6% | 6% | 11.3× | -3.1% | +12.6% |
| Aclaris Therapeutics ACRS | United States | $555M | -23% | -59% | -1,412% | n/a | n/a | n/a |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $557M | -24% | -3% | 7% | 9.0× | -5.8% | +4.1% |
| Morepen Laboratories MOREPENLAB.NS | India | $542M | +121% | +30% | 11% | n/a | n/a | n/a |
| Zhong Zhu Healthcare 600568.SS | China | $562M | -22% | -6% | -34% | n/a | n/a | n/a |
| Jenkem Technology 688356.SS | China | $563M | -30% | +52% | 11% | 30.2× | 36.4% | +11.2% |
| Senores Pharmaceuticals SENORES.NS | India | $538M | +3% | +40% | 24% | 32.2× | n/a | n/a |
| Entera Bio ENTX | United States | $568M | +163% | -100% | n/a | n/a | n/a | n/a |
| Alumis ALMS | United States | $569M | -80% | -67% | -5,375% | n/a | n/a | n/a |
| Chimin Health Management 603222.SS | China | $533M | -31% | +1% | -28% | n/a | n/a | n/a |
| Electra Therapeutics ETRA | United States | $530M | n/a | n/a | n/a | n/a | n/a | n/a |
| Jinling Pharmaceutical 000919.SZ | China | $529M | -15% | -8% | 1% | n/a | 2.4% | +5.0% |
| Supriya Lifescience SUPRIYA.NS | India | $529M | -15% | +23% | 26% | 36.2× | 28.2% | +15.8% |
| Evonile Pharma EVONILE.NS | India | $529M | n/a | -5% | 12% | n/a | 49.3% | -1.5% |
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $577M | -26% | -21% | 32% | 10.2× | -15.4% | +2.8% |
| Abbisko Cayman 2256.HK | Hong Kong | $578M | -39% | -83% | -520% | n/a | n/a | n/a |
| Oneness Biotech 4743.TWO | Taiwan | $580M | -13% | +19% | -589% | n/a | n/a | n/a |
| Lepu Biopharma 2157.HK | Hong Kong | $580M | -43% | +47% | 7% | 53.6× | n/a | n/a |